Comparative Pharmacology
Head-to-head clinical analysis: BAXDELA versus MOXIFLOXACIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAXDELA versus MOXIFLOXACIN HYDROCHLORIDE.
BAXDELA vs MOXIFLOXACIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Oral: 450 mg (as single tablet) twice daily for 5 days. Intravenous: 450 mg once daily (over 3 hours) or 300 mg twice daily (over 1 hour) for 5 days.
400 mg orally or intravenously once daily for most indications; duration varies by indication.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours in healthy adults; may be prolonged in patients with renal impairment (up to 20 hours in severe renal impairment).
Terminal elimination half-life is approximately 12-14 hours in healthy adults, allowing once-daily dosing. This is extended in severe renal impairment (creatinine clearance <30 mL/min) and in the elderly.
Renal (approximately 65% of dose as unchanged drug) and fecal (approximately 20% as metabolites and unchanged drug). Biliary excretion is minimal.
Approximately 20% of a dose is excreted unchanged in urine, with about 25% recovered as a glucuronide conjugate (M1) and a sulfate conjugate (M2). Biliary/fecal excretion accounts for about 55% of the dose, with a portion undergoing enterohepatic recirculation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic